Strategies to reduce uric acid through gut microbiota intervention
Frontiers in Microbiology · 29.08.2025 · 16
DOI: 10.3389/fmicb.2025.1654152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 29.08.2025. Verfasst von Yueying Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Medicine, Air Force Medical Center, Air Force Medical University, PLA, Beijing, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hyperuricaemia (HUA) is a metabolic disorder resulting from the dysregulation of purine metabolism. It is closely associated with gout and various metabolic syndromes, representing an increasing global public health challenge. Current treatment approaches for HUA and gout generally involve the lifelong administration of urate-lowering agents to maintain optimal serum urate concentrations. However, poor patient adherence, often due to potential hepatorenal toxicity, frequently leads to disease relapse. Recent evidence indicates that the gut microbiota plays a significant role in maintaining urate homeostasis through multiple mechanisms, including the modulation of purine metabolism, urate catabolism and excretion, regulation of inflammatory responses, and preservation of intestinal barrier integrity. These findings highlight the gut microbiota as a promising novel therapeutic target. This review synthesizes recent progress in three key areas: (1) the relationship between the gut microbiota and HUA; (2) microbial mechanisms underlying urate-lowering effects, such as microbial purine and urate metabolism, regulation of urate transporters like ABCG2, and production of anti-inflammatory metabolites; and (3) microbiota-based therapeutic interventions, including probiotics, engineered bacterial strains, fecal microbiota transplantation, and pharmabiotic strategies. Additionally, we explore the translational potential of microbiota modulation in clinical settings and outline directions for future research. By integrating mechanistic understanding with therapeutic innovation, this review offers researchers and clinicians a comprehensive framework for advancing microbiota-targeted approaches in the management of hyperuricaemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Clinical Medicine, Air Force Medical Center, Air Force Medical University, PLA, Beijing, China.
- Department of Aeromedical Support & Flight Safety, Air Force Medical Center, Air Force Medical University, PLA, Beijing, China.
- Department of Cardiovascular Medicine, Air Force Medical Center, Air Force Medical University, PLA, Beijing, China.
Zitieren
APA
Cui, Y., An, P., Li, F., Duan, F., Mei, Z., Ye, Q., Wang, G., Zhang, H., & Luo, Y. (2025). Strategies to reduce uric acid through gut microbiota intervention. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1654152
Vancouver
Cui Y, An P, Li F, Duan F, Mei Z, Ye Q, et al. Strategies to reduce uric acid through gut microbiota intervention. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1654152
BibTeX
@article{Cui2025,
author = {Cui, Yueying and An, Peiyu and Li, Feng and Duan, Fengsen and Mei, Zusong and Ye, Qiao and Wang, Guangyun and Zhang, Haitao and Luo, Yuan},
title = {Strategies to reduce uric acid through gut microbiota intervention},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1654152}
}
EUVIMED